Kymera Therapeutics, Inc. (KYMR)

38.73 +0.43 (+1.12%) As of 11:06AM EDT. Market open.

Kymera Therapeutics, Inc.

200 Arsenal Yards Boulevard
Suite 230
Watertown, MA 02472
United States
857 285 5300
https://www.kymeratx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 186

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Bruce L. Booth DPHIL, Ph.D.	Co-Founder & Independent Chairman	75k	N/A	1974
Dr. Nello Mainolfi M.D., Ph.D.	Co-Founder, President, CEO & Director	1.08M	457.97k	1979
Mr. Bruce N. Jacobs CFA	Chief Financial Officer	671.2k	249.77k	N/A
Dr. Jeremy G. Chadwick Ph.D.	Chief Operating Officer	883k	N/A	1963
Ms. Ellen V. Chiniara Esq., J.D.	Chief Legal Officer & Corporate Secretary	640.35k	N/A	1959
Dr. Jared A. Gollob M.D.	Chief Medical Officer	723.6k	N/A	1965
Ms. Karen Weisbach	Head of People & Culture	N/A	N/A	N/A
Dr. Juliet Williams B.A Ph.D.	Head of Research	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Kymera Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.